 Home > Active Ingredient News > Antitumor Therapy > Front Oncol: Comparison of the direct efficacy of bevacizumab or pembrolizumab combined with pemetrexed + platinum-based chemotherapy in the first-line treatment of driver-gene-negative advanced non-squamous non-small cell lung cancer (NSCLC)

Front Oncol: Comparison of the direct efficacy of bevacizumab or pembrolizumab combined with pemetrexed + platinum-based chemotherapy in the first-line treatment of driver-gene-negative advanced non-squamous non-small cell lung cancer (NSCLC)

 Last Update: 2021-10-10
 Source: Internet
 Author: User

Tags

burkholderia cepacia treatment

pancreatic cancer association

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Bevacizumab or pembrolizumab combined with pemetrexed + platinum-based chemotherapy are recommended as first-line treatment for patients with advanced non-squamous non-small cell lung cancer ( NSCLC ) with negative driver genes

The study retrospectively collected medical records of 102 EGFR/ALK/ROS1-negative stage IIIB-IV non-squamous NSCLC patients who were treated at Fudan University Shanghai Cancer Center from December 2018 to April 2021.

Among 102 patients included in the study, 49 patients received pembrolizumab-pemetrexed + platinum treatment, and 57.

At the time of the data cutoff, the median follow-up time of the pembrolizumab group was 8.

The ORR of the pembrolizumab group and the bevacizumab group were 36.

Efficacy evaluation

Multivariate analysis showed that the baseline high lymphoid mononuclear cell ratio (LMR) (>1.

When the absolute number of eosinophils (AEC)>0.

Marker exploration

Adverse events (AEs) of any grade occurred in 46 cases (93.

In summary, studies have shown that bevacizumab or pembrolizumab combined with pemetrexed + platinum-based chemotherapy for first-line treatment of driver-gene-negative advanced non-squamous non-small cell lung cancer (NSCLC) has comparable efficacy and toxicity
.
Studies have shown that bevacizumab or pembrolizumab combined with pemetrexed + platinum-based chemotherapy for first-line treatment of driver-gene-negative advanced non-squamous non-small cell lung cancer (NSCLC) has comparable efficacy and toxicity
.
Studies have shown that bevacizumab or pembrolizumab combined with pemetrexed + platinum-based chemotherapy for first-line treatment of driver-gene-negative advanced non-squamous non-small cell lung cancer (NSCLC) has comparable efficacy and toxicity
.

Original source:

Liao J, Liu C, Long Q, et al(2021) Direct Comparison Between the Addition of Pembrolizumab or Bevacizumab for Chemotherapy-Based First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer Lacking Driver Mutations.
Front.
Oncol.
11:752545.
doi: 10.
3389/fonc.
2021.
752545

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.